Assessment of early response to imatinib 800 mg after 400 mg progression by 18F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors. (March 2015)

• Record Type: Journal Article
• Authors: Chacón, Matías; Eleta, Martín; Espindola, Adriel Rodríguez; Roca, Enrique; Méndez, Guillermo; Rojo, Sandra; Pupareli, Carmen
• Is Part Of: Future oncology. Volume 11:Number 6(2015)
• Page Start: 953
• Page End: 964
• Publication Date: 2015-03
• Subjects: assessment -- early -- FDG -- GIST -- imatinib 800 mg -- metabolic -- PET; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.292
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : Introduction: Imatinib is the standard first-line therapy for advanced gastrointestinal stromal tumor. 18 F-fluorodeoxyglucose PET computed tomography (FDG PET/CT) shows a faster response than computed tomography in nonpretreated patients.Patients & methods: After disease progression on imatinib 400 mg, 16 patients were exposed to 800 mg. Tumor response was evaluated by FDG PET/CT on days 7 and 37. Primary objective was to correlate early metabolic response (EMR) with progression-free survival (PFS).Results: EMR by FDG PET/CT scan was not predictive of PFS. Median PFS in these patients was 3 months. Overall survival was influenced by gastric primary site (p = 0.05).Conclusion: The assessment of EMR by FDG PET/CT in patients with advanced gastrointestinal stromal tumor exposed to imatinib 800 mg was not predictive of PFS or overall survival.